Fighting Chronic Inflammatory Diseases and Cancer With Precision
OncoOne's primary goal is to uncover and deliver precise targeted therapies and solutions.
Our Founders
OncoOne's founders, Randolf Kerschbaumer, Michael Thiele, and Alexander Schinagl, are the pioneers behind the novel therapeutic target oxMIF, a disease-associated isoform of the Macrophage Migration Inhibitory Factor (MIF), playing a crucial role in shaping the future of precision medicine. We conceive of ourselves as wizards of antibody engineering, which underpins our ambition to provide innovative targeted therapies with curative potential, focusing on improving patients' quality of life rather than just managing symptoms.
We Are a Key Player in Shaping the Future of Precision Medicine.
OncoOne’s approach is designed to overcome limitations in current systemic therapeutics and address chronic inflammatory diseases and cancer, with the ambition to effectively improve patient outcomes and quality of life. Our world-class team of antibody engineers specializes in developing and fine-tuning unique monoclonal antibodies, customized to meet complex therapeutic requirements to effectively address chronic inflammatory diseases and cancer. We strive to revolutionize treatments for underserved patient populations where substantial medical needs persist. By leveraging collaborations with leading experts and cutting-edge technologies like AI and in-depth data analysis, we optimize our clinical development program to address unmet clinical needs.
“Our vision runs deep, and our path is clear. We're fully committed to making a meaningful difference in people's lives through the innovative targeted therapies we create together. It's our team's dedication to innovation and inclusivity, coupled with unwavering integrity, that drives every aspect of our work.”
- Randolf Kerschbaumer, CEO
“Our vision runs deep, and our path is clear. We’re fully committed to making a meaningful difference in people’s lives through the innovative targeted therapies we create together. It’s our team’s dedication to innovation and inclusivity, coupled with unwavering integrity, that drives every aspect of our work.”
- Randolf Kerschbaumer, CEO
